Research & Development

Our Science

Assembly is forging new paths to curing infectious diseases, focusing initially on novel curative small molecule therapies for chronic hepatitis B virus (HBV) infection and microbiotic therapies for Clostridium difficile (C. difficile) infections (CDI). The company also is developing its versatile, enabling Gemicel® platform technology, which allows for targeted oral delivery of live biotherapeutics, vaccines, complex macromolecules and small molecules targeted to specific regions of the GI tract.